Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer

Numerous comparative clinical trials have been conducted evaluating combina tion hormonal therapy involving the aromatase inhibitor aminoglutethimide, but there is no evidence for any superiority of this approach over single-a gent therapy alone. The advent of new aromatase inhibitors with greater pot ency, selectivity, and better tolerability has prompted a reconsideration o f the combined therapy approach, with attention being focused on pharmacolo gic and endocrinologic clinical research. The value of combining newer arom atase inhibitors with other hormonal agents remains to be established.